Processing...
Clinical Trials for Uterine Cancer
Search
Search
There are 163 active trials for advanced/metastatic uterine cancer.
Click on a trial to see more information.
163 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with previously treated, advanced solid tumors harboring oncogenic PIK3CA mutations, including endometrial, HR-positive/HER2-negative or HER2-low breast, head and neck, gynecologic, and colorectal cancers, receive oral CGT6297. CGT6297 is a mutant-selective, wild-type-sparing allosteric PI3Kα inhibitor with activity against PIK3CA H1047R and potentially E545K mutations.
ClinicalTrials.gov ID: NCT07383506
TrialFetch AI summary: Adults with unresectable or metastatic solid tumors after prior immune-checkpoint or related T-cell-directed therapy and appropriate standard therapy may receive oral ARV-6723 alone or with pembrolizumab. ARV-6723 is an investigational PROTAC that degrades HPK1/MAP4K1 to enhance antitumor immune signaling; later cohorts may include investigator-selected standard of care.
ClinicalTrials.gov ID: NCT07749586
TrialFetch AI summary: Adults with locally advanced or metastatic platinum-resistant ovarian, fallopian-tube, or primary peritoneal cancer, or endometrial cancer, receive ARR-002 in dose-escalation or expansion cohorts. ARR-002 is an investigational antibody–drug conjugate targeting MUC16 and NaPi2b that delivers the microtubule-disrupting payload monomethyl auristatin E.
ClinicalTrials.gov ID: NCT07755436
TrialFetch AI summary: Adults with ECOG 0–1 and advanced selected solid tumors who have exhausted or are ineligible for standard treatment receive oral TT-10 (PORT-6), an adenosine A2A receptor antagonist, oral TT-4 (PORT-7), an adenosine A2B receptor antagonist, or both. Eligible tumor types vary by cohort and include RCC, CRPC, NSCLC, head and neck, colorectal, endometrial, and ovarian cancers.
ClinicalTrials.gov ID: NCT04969315
TrialFetch AI summary: Adults with previously treated, unresectable locally advanced or metastatic NSCLC, head and neck squamous cell carcinoma, cervical cancer, or uterine cancer are eligible if their tumors express the NEO-201 antigen in at least 10% of cells. Treatment combines NEO-201, an investigational antibody targeting tumor-associated core 1 and extended core 1 O-glycans, with the PD-1 inhibitor pembrolizumab.
ClinicalTrials.gov ID: NCT03476681
TrialFetch AI summary: Adults with measurable metastatic or unresectable cancer, ECOG 0–1, and no suitable standard treatment option may receive oral NX-1607, a CBL-B inhibitor intended to enhance T-cell antitumor activity. Selected tumor cohorts receive NX-1607 with paclitaxel.
ClinicalTrials.gov ID: NCT05107674
TrialFetch AI summary: Adults with unresectable locally advanced or metastatic antigen-rich solid tumors and no more than three prior lines of therapy for advanced disease receive intravenous STAR0602 (invikafusp alfa) monotherapy. This investigational antibody–cytokine fusion targets T-cell receptor Vβ6/Vβ10 subsets and stimulates the IL-2 receptor to expand potentially tumor-reactive T cells.
ClinicalTrials.gov ID: NCT05592626
TrialFetch AI summary: Adults with advanced solid tumors or lymphoma and no remaining standard or curative treatment option receive oral VMD-928 monotherapy. Patients generally require TrkA overexpression or an NTRK1 fusion; VMD-928 is an investigational allosteric TrkA/NTRK1 inhibitor.
ClinicalTrials.gov ID: NCT03556228
TrialFetch AI summary: Adults with measurable metastatic solid tumors expressing KK-LC-1 in ≥10% of tumor cells and carrying HLA-A*01:01, particularly those with gastric, non–small cell lung, triple-negative breast, or cervical cancer, may enroll after receiving or declining standard systemic therapy. Treatment consists of cyclophosphamide/fludarabine conditioning, a single infusion of autologous TCR-engineered T cells targeting an HLA-A*01:01–presented KK-LC-1 peptide, and aldesleukin.
ClinicalTrials.gov ID: NCT05483491
TrialFetch AI summary: Adults with recurrent or metastatic GRPR-expressing mCRPC, HR-positive/HER2-negative breast cancer, colorectal cancer, cervical cancer, cutaneous melanoma, or NSCLC are eligible if they have a lesion with uptake greater than liver on GRPR imaging; recurrent disease must have progressed after at least two systemic therapies. Participants receive up to four cycles of investigational ²¹²Pb-DOTAM-GRPR1, a GRPR-targeted radiopharmaceutical that delivers DNA-damaging alpha radiation.
ClinicalTrials.gov ID: NCT05283330